Free Trial

Inogen (NASDAQ:INGN) Earns Buy Rating from Analysts at B. Riley

Inogen logo with Medical background

B. Riley initiated coverage on shares of Inogen (NASDAQ:INGN - Free Report) in a research report report published on Sunday, MarketBeat Ratings reports. The firm issued a buy rating and a $14.00 price target on the medical technology company's stock. B. Riley also issued estimates for Inogen's Q2 2025 earnings at ($0.22) EPS, Q3 2025 earnings at ($0.18) EPS, Q4 2025 earnings at ($0.30) EPS, FY2025 earnings at ($0.95) EPS, Q1 2026 earnings at ($0.22) EPS, Q2 2026 earnings at ($0.17) EPS, Q3 2026 earnings at ($0.15) EPS, Q4 2026 earnings at ($0.19) EPS and FY2026 earnings at ($0.72) EPS.

Other equities analysts have also recently issued reports about the stock. Needham & Company LLC raised shares of Inogen from a "hold" rating to a "moderate buy" rating and set a $12.00 price objective on the stock in a research note on Thursday, May 22nd. Stifel Nicolaus cut their price target on Inogen from $10.00 to $7.00 and set a "hold" rating on the stock in a research note on Thursday, May 8th. Finally, Wall Street Zen cut Inogen from a "buy" rating to a "hold" rating in a research note on Wednesday, February 26th.

Read Our Latest Research Report on INGN

Inogen Stock Up 0.6%

INGN stock traded up $0.04 during trading on Friday, hitting $6.64. The company had a trading volume of 342,887 shares, compared to its average volume of 242,009. The firm has a 50-day moving average price of $6.63 and a 200-day moving average price of $8.24. Inogen has a 12 month low of $5.70 and a 12 month high of $13.33. The stock has a market cap of $178.55 million, a price-to-earnings ratio of -5.77 and a beta of 1.64.

Inogen (NASDAQ:INGN - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The medical technology company reported ($0.25) EPS for the quarter, topping analysts' consensus estimates of ($0.52) by $0.27. Inogen had a negative return on equity of 14.76% and a negative net margin of 8.08%. The firm had revenue of $82.28 million during the quarter, compared to analyst estimates of $79.57 million. Equities analysts expect that Inogen will post -1.73 EPS for the current year.

Institutional Trading of Inogen

Institutional investors and hedge funds have recently bought and sold shares of the stock. AlphaQuest LLC bought a new position in Inogen in the fourth quarter valued at approximately $43,000. GAMMA Investing LLC boosted its holdings in shares of Inogen by 5,738.9% in the 1st quarter. GAMMA Investing LLC now owns 5,547 shares of the medical technology company's stock valued at $400,000 after buying an additional 5,452 shares during the last quarter. Meeder Asset Management Inc. acquired a new stake in shares of Inogen in the 4th quarter valued at approximately $56,000. Integrated Quantitative Investments LLC bought a new position in shares of Inogen in the 4th quarter valued at about $92,000. Finally, Intech Investment Management LLC acquired a new stake in shares of Inogen in the fourth quarter valued at approximately $94,000. Institutional investors own 89.94% of the company's stock.

About Inogen

(Get Free Report)

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.

Read More

Should You Invest $1,000 in Inogen Right Now?

Before you consider Inogen, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Inogen wasn't on the list.

While Inogen currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 Made in America Stocks Under $20 You Need to See!
3 Cheap Growth Stocks Set to Explode This Summer
The Next NVIDIA? Quantum Computing Stocks Set for Explosive Growth

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines